Page last updated: 2024-10-21

enprofylline and Cardiac Complex, Premature

enprofylline has been researched along with Cardiac Complex, Premature in 1 studies

enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.

Research Excerpts

ExcerptRelevanceReference
"Twenty-four patients (five women) aged 53-72 yr with both ischemic heart disease and asthma or chronic bronchitis receiving oral beta 2-agonists also received additional bronchodilating therapy with theophylline (600 mg daily), enprofylline (600 mg daily) or placebo."5.06Arrhythmogenicity from combined bronchodilator therapy in patients with obstructive lung disease and concomitant ischemic heart disease. ( Conradson, TB; Eklundh, G; Olofsson, B; Pahlm, O; Persson, G, 1987)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Conradson, TB1
Eklundh, G1
Olofsson, B1
Pahlm, O1
Persson, G1

Trials

1 trial available for enprofylline and Cardiac Complex, Premature

ArticleYear
Arrhythmogenicity from combined bronchodilator therapy in patients with obstructive lung disease and concomitant ischemic heart disease.
    Chest, 1987, Volume: 91, Issue:1

    Topics: Aged; Asthma; Bronchitis; Cardiac Complexes, Premature; Clinical Trials as Topic; Coronary Disease;

1987